Related Experiment Video
Updated: Aug 6, 2026
09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Multiple system atrophy: cure and care
Jolanda Buonocore1,2,3, Bianca Caliò1, Fabian Leys1
1Department of Neurology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria.
Journal of Neural Transmission (Vienna, Austria : 1996)
|July 25, 2026
Summary
Multiple system atrophy (MSA) is a rare neurodegenerative disease. Early diagnosis and targeted therapies are crucial for managing MSA, despite current treatment limitations.
Area of Science:
- Neuroscience
- Neuropathology
Background:
- Multiple system atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder.
- Characterized by autonomic failure, parkinsonism, and cerebellar ataxia.
- Etiology is poorly understood; neuropathology involves α-synuclein accumulation in oligodendroglia.
Purpose of the Study:
- To review recent advances in MSA diagnosis and treatment.
- To highlight challenges in early disease detection.
- To discuss emerging care models and future research directions.
Main Methods:
- Review of current literature on MSA diagnostics and therapeutics.
- Analysis of neuropathological findings related to α-synuclein.
- Examination of advancements in fluid biomarkers and multimodal imaging.
Main Results:
- Improved diagnostic criteria and biomarker development aid recognition.
- Early diagnosis remains challenging, especially in the prodromal phase.
- Therapeutic strategies targeting α-synuclein have shown limited clinical benefit.
Conclusions:
- Advances in biomarkers and imaging may improve early detection and monitoring.
- Current treatments are supportive, focusing on symptom management.
- Multidisciplinary and telemedicine approaches can enhance patient care and access.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...